| pubmed-article:19967557 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19967557 | lifeskim:mentions | umls-concept:C0006142 | lld:lifeskim |
| pubmed-article:19967557 | lifeskim:mentions | umls-concept:C0013216 | lld:lifeskim |
| pubmed-article:19967557 | lifeskim:mentions | umls-concept:C1704632 | lld:lifeskim |
| pubmed-article:19967557 | lifeskim:mentions | umls-concept:C0871261 | lld:lifeskim |
| pubmed-article:19967557 | lifeskim:mentions | umls-concept:C0079429 | lld:lifeskim |
| pubmed-article:19967557 | lifeskim:mentions | umls-concept:C2911692 | lld:lifeskim |
| pubmed-article:19967557 | lifeskim:mentions | umls-concept:C1706817 | lld:lifeskim |
| pubmed-article:19967557 | lifeskim:mentions | umls-concept:C0681842 | lld:lifeskim |
| pubmed-article:19967557 | lifeskim:mentions | umls-concept:C0600558 | lld:lifeskim |
| pubmed-article:19967557 | lifeskim:mentions | umls-concept:C0302350 | lld:lifeskim |
| pubmed-article:19967557 | lifeskim:mentions | umls-concept:C1956267 | lld:lifeskim |
| pubmed-article:19967557 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:19967557 | pubmed:dateCreated | 2010-9-16 | lld:pubmed |
| pubmed-article:19967557 | pubmed:abstractText | Several gene expression profiles have been reported to predict breast cancer response to neoadjuvant chemotherapy. These studies often consider breast cancer as a homogeneous entity, although higher rates of pathologic complete response (pCR) are known to occur within the basal-like subclass. We postulated that profiles with higher predictive accuracy could be derived from a subset analysis of basal-like tumors in isolation. Using a previously described "intrinsic" signature to differentiate breast tumor subclasses, we identified 50 basal-like tumors from two independent clinical trials associated with gene expression profile data. 24 tumor data sets were derived from a 119-patient neoadjuvant trial at our institution and an additional 26 tumor data sets were identified from a published data set (Hess et al. J Clin Oncol 24:4236-4244, 2006). The combined 50 basal-like tumors were partitioned to form a 37 sample training set with 13 sequestered for validation. Clinical surveillance occurred for a mean of 26 months. We identified a 23-gene profile which predicted pCR in basal-like breast cancers with 92% predictive accuracy in the sequestered validation data set. Furthermore, distinct cluster of patients with high rates of cancer recurrence was observed based on cluster analysis with the 23-gene signature. Disease-free survival analysis of these three clusters revealed significantly reduced survival in the patients of this high recurrence cluster. We identified a 23-gene signature which predicts response of basal-like breast cancer to neoadjuvant chemotherapy as well as disease-free survival. This signature is independent of tissue collection method and chemotherapeutic regimen. | lld:pubmed |
| pubmed-article:19967557 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19967557 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19967557 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19967557 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19967557 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:19967557 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19967557 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:19967557 | pubmed:issn | 1573-7217 | lld:pubmed |
| pubmed-article:19967557 | pubmed:author | pubmed-author:FlemingTimoth... | lld:pubmed |
| pubmed-article:19967557 | pubmed:author | pubmed-author:LinYiingY | lld:pubmed |
| pubmed-article:19967557 | pubmed:author | pubmed-author:LinShinS | lld:pubmed |
| pubmed-article:19967557 | pubmed:author | pubmed-author:WatsonMarkM | lld:pubmed |
| pubmed-article:19967557 | pubmed:author | pubmed-author:TrinkausKathr... | lld:pubmed |
| pubmed-article:19967557 | pubmed:author | pubmed-author:AftRebecca... | lld:pubmed |
| pubmed-article:19967557 | pubmed:author | pubmed-author:WeilbaecherKa... | lld:pubmed |
| pubmed-article:19967557 | pubmed:author | pubmed-author:NaughtonMicha... | lld:pubmed |
| pubmed-article:19967557 | pubmed:author | pubmed-author:KuoSachaS | lld:pubmed |
| pubmed-article:19967557 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:19967557 | pubmed:volume | 123 | lld:pubmed |
| pubmed-article:19967557 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19967557 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19967557 | pubmed:pagination | 691-9 | lld:pubmed |
| pubmed-article:19967557 | pubmed:meshHeading | pubmed-meshheading:19967557... | lld:pubmed |
| pubmed-article:19967557 | pubmed:meshHeading | pubmed-meshheading:19967557... | lld:pubmed |
| pubmed-article:19967557 | pubmed:meshHeading | pubmed-meshheading:19967557... | lld:pubmed |
| pubmed-article:19967557 | pubmed:meshHeading | pubmed-meshheading:19967557... | lld:pubmed |
| pubmed-article:19967557 | pubmed:meshHeading | pubmed-meshheading:19967557... | lld:pubmed |
| pubmed-article:19967557 | pubmed:meshHeading | pubmed-meshheading:19967557... | lld:pubmed |
| pubmed-article:19967557 | pubmed:meshHeading | pubmed-meshheading:19967557... | lld:pubmed |
| pubmed-article:19967557 | pubmed:meshHeading | pubmed-meshheading:19967557... | lld:pubmed |
| pubmed-article:19967557 | pubmed:meshHeading | pubmed-meshheading:19967557... | lld:pubmed |
| pubmed-article:19967557 | pubmed:meshHeading | pubmed-meshheading:19967557... | lld:pubmed |
| pubmed-article:19967557 | pubmed:meshHeading | pubmed-meshheading:19967557... | lld:pubmed |
| pubmed-article:19967557 | pubmed:meshHeading | pubmed-meshheading:19967557... | lld:pubmed |
| pubmed-article:19967557 | pubmed:meshHeading | pubmed-meshheading:19967557... | lld:pubmed |
| pubmed-article:19967557 | pubmed:meshHeading | pubmed-meshheading:19967557... | lld:pubmed |
| pubmed-article:19967557 | pubmed:meshHeading | pubmed-meshheading:19967557... | lld:pubmed |
| pubmed-article:19967557 | pubmed:meshHeading | pubmed-meshheading:19967557... | lld:pubmed |
| pubmed-article:19967557 | pubmed:meshHeading | pubmed-meshheading:19967557... | lld:pubmed |
| pubmed-article:19967557 | pubmed:meshHeading | pubmed-meshheading:19967557... | lld:pubmed |
| pubmed-article:19967557 | pubmed:meshHeading | pubmed-meshheading:19967557... | lld:pubmed |
| pubmed-article:19967557 | pubmed:meshHeading | pubmed-meshheading:19967557... | lld:pubmed |
| pubmed-article:19967557 | pubmed:meshHeading | pubmed-meshheading:19967557... | lld:pubmed |
| pubmed-article:19967557 | pubmed:meshHeading | pubmed-meshheading:19967557... | lld:pubmed |
| pubmed-article:19967557 | pubmed:year | 2010 | lld:pubmed |
| pubmed-article:19967557 | pubmed:articleTitle | A gene expression signature that predicts the therapeutic response of the basal-like breast cancer to neoadjuvant chemotherapy. | lld:pubmed |
| pubmed-article:19967557 | pubmed:affiliation | Department of Surgery, Washington University School of Medicine St. Louis, 660 South Euclid Avenue, Campus Box 8109, St. Louis, MO 63110, USA. | lld:pubmed |
| pubmed-article:19967557 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:19967557 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:19967557 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:19967557 | lld:pubmed |
